MQS Management LLC Has $832,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

by · The Cerbat Gem

MQS Management LLC boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 303.4% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 10,681 shares of the company’s stock after acquiring an additional 8,033 shares during the quarter. MQS Management LLC’s holdings in AstraZeneca were worth $832,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of AZN. McClarren Financial Advisors Inc. boosted its stake in shares of AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. GHP Investment Advisors Inc. acquired a new stake in AstraZeneca in the second quarter valued at approximately $26,000. Capital Performance Advisors LLP acquired a new stake in AstraZeneca in the third quarter valued at approximately $28,000. Pathway Financial Advisers LLC bought a new stake in shares of AstraZeneca during the first quarter worth $29,000. Finally, RFP Financial Group LLC increased its holdings in shares of AstraZeneca by 56.3% during the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock worth $33,000 after buying an additional 178 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Trading Up 0.6 %

NASDAQ AZN opened at $65.19 on Wednesday. The firm has a market capitalization of $202.13 billion, a PE ratio of 31.49, a price-to-earnings-growth ratio of 1.20 and a beta of 0.47. The business’s 50-day moving average price is $76.20 and its two-hundred day moving average price is $78.47. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AZN. TD Cowen raised their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and an average price target of $89.75.

View Our Latest Stock Report on AZN

AstraZeneca Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Recommended Stories

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).